Clinical Trial Update: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy [Phase 2]

View source ↗

Summary

This Phase II randomized, open-label trial evaluates whether NiraParib maintenance after 3 cycles of platinum-based chemotherapy is non-inferior to maintenance …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: North Eastern German Society of Gynaecological Oncology | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: RECRUITING